--
Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care
--
The posters highlight two health economic models developed for OLINVYK (oliceridine) injection, which estimate the budget impact of OLINVYK compared to IV morphine when used on-demand in a hospital setting for postoperative pain. A “Base Case” model assumes a broad patient population. A “High Risk” model limits the population to patients who are both elderly (≥ 65 years old) and obese (BMI ≥ 30 kg/m2), part of the Company’s initial core focus for launch. Both models were developed using AE incidence rates from the OLINVYK Phase 3 program and AE cost estimates from the published literature and claims data as referenced in the posters.
“Publishing these health economic models is the latest accomplishment in our ongoing launch of OLINVYK,” said
One of the posters, “Budget Impact Analysis for Oliceridine in the Management of Moderate-to Severe Acute Postoperative Pain,” was selected by the conference for a Gold Ribbon. This designation was awarded based on the same criteria used by
Poster Details
- Base Case Model: “Budget Impact Analysis for Oliceridine in the Management of Moderate-to Severe Acute Postoperative Pain” (Poster #U12)
- OLINVYK is associated with a
~$230,000 decrease in total cost of care per 1,000 patients compared to IV morphine. - These cost savings are due to reduced AEs for OLINVYK-treated patients, as observed in the Phase 3 pivotal trials, and using a conservative, low-end estimate of AE costs based on government and published literature sources.
- OLINVYK is associated with a
- High Risk Model: “Cost Effectiveness Analysis of Oliceridine Compared with Morphine in The Management of Postoperative Moderate to Severe Acute Pain in a High Risk Population” (Poster #U18)
- OLINVYK is associated with savings of
~$364,000 in total cost of care per 1,000 patients, due to reduced AEs compared to IV morphine. The model estimates that the total cost of care associated with IV morphine would exceed$1.25M per 1,000 patients.
- OLINVYK is associated with savings of
All posters can be found at https://www.trevena.com/publications. While the cost savings in these health economic models cannot be guaranteed, they are based on generally accepted methodology, and pharmacy and therapeutics committees typically review health economic models when making drug formulary decisions.
About OLINVYK™ (oliceridine) injection
OLINVYK is a new chemical entity approved by the FDA in
About Trevena
For more information, please visit www.Trevena.com
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the
For more information, please contact:
Investor Contact:
Managing Director
daniel@lifesciadvisors.com
(617) 430-7576
PR & Media Contact:
Director
Sasha.Bennett@clydegroup.com
(239) 248-3409
Source:
2021 GlobeNewswire, Inc., source